CZ / EN

Endocrine Disruption in CLP: First insights into the new ECHA Guidance (FREE webinar)

Endocrine Disruption in CLP: First insights into the new ECHA Guidance (FREE webinar)

The new ECHA Guidance on the Application of CLP Criteria is about to shake up the chemical industry with its heavy focus on endocrine disruption. Join experts in the field sharing their first impressions of the guidance.

Information

  • Date: 10th October 2024
  • Time: 10:00 CEST
  • Location: ZOOM platform

REGISTER HERE

Key Discussion Points:

  • Content and scope of the new ECHA guidance
  • Understanding the endocrine disruption criteria
  • ECHA dealings with previous comments on guidance drafts
  • Practical advice for chemical producers and regulatory affairs teams

Adam Jonáš

Ecotoxicology & Toxicology Expert (REGARTIS)

Adam is our toxicology and ecotoxicology expert. He is involved in this field since 2007. He started in academia performing experimental work to investigate the endocrine activity, acute toxicity, and neurotoxicity of various substances, mixtures, or environmental samples. He published several articles in leading toxicology and ecotoxicology journals. Later he had several regulatory roles in industry focused on biocides, plant protection, REACH, and CLP in the EU and other regions with proven track of successful registrations. He has experience with the endocrine disruptors assessment of plant protection and biocidal active substances under the current EFSA and ECHA guidance. He also helped to designed and study monitored numerous toxicological and ecotoxicological studies very often with very specific and difficult to be tested substances.

Aleš Bartl

EU Regulatory Partner (Keller and Heckman LLP)

Ales Bartl has a broad experience in EU product regulatory law, including REACH, Classification, Labelling, and Packaging (CLP) regulation, Biocidal Products Regulation (BPR), medical devices, electronic products, and general product compliance and product safety. He advises on regulatory compliance of a broad range of products marketed in the EU and represents clients before EU and national competent authorities on compliance and enforcement issues, including product withdrawals and recalls. Ales also represents clients before the Court of Justice of the European Union and the Board of Appeal of European Chemicals Agency.

Find out how we can help you assess products for endocrine disruption properties.